News BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Real-time Estimate Cboe BZX Other stock markets 03:48:11 2024-04-25 pm EDT			5-day change	1st Jan Change
24.36 ^USD	-2.68%		-2.57%	-39.78%

Apr. 07	BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement	CI
Mar. 20	JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BridgeBio Pharma : BBIO – BBO-8520 – 2024 AACR – Rapid and Complete Blockade of Effector Binding Results	Apr. 23	PU
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	Apr. 10	GL
BridgeBio Pharma Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 study in Patients with Transthyretin Amyloid Cardiomyopathy	Apr. 08	AQ
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	Apr. 07	AQ
BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement	Apr. 07	CI
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	Apr. 07	GL
JPMorgan Raises BridgeBio Pharma Price Target to $45 From $35, Maintains Overweight Rating	Mar. 20	MT
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	Mar. 20	GL
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $70 From $60, Maintains Overweight Rating	Mar. 19	MT
BridgeBio Pharma : BBIO – Encaleret for ADH1 – ACMG 2024 Genetic Testing	Mar. 14	PU
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $60 From $50, Maintains Overweight Rating	Mar. 11	MT
BridgeBio Pharma Prices $250 Million Stock Offering	Mar. 06	MT
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock	Mar. 05	GL
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	Mar. 05	MT
BridgeBio Pharma Commences $250 Million Share Offering	Mar. 04	MT
BridgeBio Pharma Announces Proposed Public Offering of Common Stock	Mar. 04	GL
Mizuho Securities Trims Price Target on BridgeBio Pharma to $53 From $60, Keeps Buy Rating	Mar. 04	MT
BridgeBio Pharma Sells License for Potential Heart Disease Treatment to Bayer in Deal Worth up to $310 Million	Mar. 04	MT
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM	Mar. 04	GL
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe	Mar. 04	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Summary

Filters